---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000034"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T11:24:34.019901+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Novocure's PANOVA-3 Phase 3 trial meets primary endpoint in pancreatic cancer; plans regulatory filings

## Summary
- PANOVA-3 met primary endpoint: mOS 16.20 months (TTFields) vs 14.16 months (control), HR=0.819, p=0.039 (N=571).
- Survival rate benefit increased over time: 13% improvement at 12 months, 33% improvement at 24 months.
- TTFields therapy was well-tolerated; safety consistent with prior studies.
- Novocure plans regulatory filings in U.S., EU, Japan, and other key markets based on PANOVA-3.
- This is Novocure's third positive Phase 3 trial in two years; full results at upcoming congress.

## SEC filing metadata
- accession: 0001645113-24-000034
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000034/0001645113-24-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000034/nvcr-20241202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000034
- JSON: https://secwatch.observer/filing/0001645113-24-000034.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.